A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma

NCT06143579 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Potentially Resectable Hepatocellular Carcinoma

Interventions

DRUG: FOLFOX-HAIC+Lenvatinib+Envolizumab

Sponsor

Sun Yat-sen University